A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs GLPG 2222 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Galapagos NV
- 01 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2017.
- 01 Aug 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.